Biotech News

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics (AQST)Aquestive Therapeutics2026-06-25 13:46 ESTFinancing

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the

Open original release

Related news

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

View all latest news

Aquestive Therapeutics

Aquestive Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

AQSTAquestive Therapeutics2026-06-26 09:40 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-06-26 09:40 EST

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQSTAquestive Therapeutics2026-06-26 09:40 EST

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

AQSTAquestive Therapeutics2026-06-26 09:40 EST

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

AQSTAquestive Therapeutics2026-06-26 09:40 EST

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States